Company Results (links open in a new window)
|
Date (document was filed at Companies House)
|
Type
|
Description (of the document filed at Companies House)
|
View / Download (PDF file, link opens in new window)
|
|
23 Sep 2024 |
TM01 |
Termination of appointment of Thomas Whittle as a director on 20 September 2024
|
|
|
21 Aug 2024 |
AA |
Audit exemption subsidiary accounts made up to 31 December 2023
|
|
|
21 Aug 2024 |
PARENT_ACC |
Consolidated accounts of parent company for subsidiary company period ending 31/12/23
|
|
|
21 Aug 2024 |
AGREEMENT2 |
Notice of agreement to exemption from audit of accounts for period ending 31/12/23
|
|
|
21 Aug 2024 |
GUARANTEE2 |
Audit exemption statement of guarantee by parent company for period ending 31/12/23
|
|
|
13 May 2024 |
CS01 |
Confirmation statement made on 13 May 2024 with updates
|
|
|
20 Oct 2023 |
PSC05 |
Change of details for Glaxosmithkline Consumer Healthcare Holdings Limited as a person with significant control on 20 October 2023
|
|
|
17 Oct 2023 |
PSC05 |
Change of details for Glaxosmithkline Consumer Healthcare Holdings Limited as a person with significant control on 19 July 2022
|
|
|
22 Sep 2023 |
AA |
Full accounts made up to 31 December 2022
|
|
|
18 Aug 2023 |
CERTNM |
Company name changed gsk consumer healthcare holdings (no.3) LIMITED\certificate issued on 18/08/23
-
NM01 ‐
Change of name by resolution
-
RES15 ‐
Change company name resolution on 2023-08-02
|
|
|
05 Jun 2023 |
CH02 |
Director's details changed for Haleon Uk Corporate Secretary Limited on 18 July 2022
|
|
|
05 Jun 2023 |
CH02 |
Director's details changed for Haleon Uk Corporate Director Limited on 18 July 2022
|
|
|
31 May 2023 |
AP01 |
Appointment of Mr Thomas Whittle as a director on 11 May 2023
|
|
|
23 May 2023 |
CS01 |
Confirmation statement made on 15 May 2023 with updates
|
|
|
17 May 2023 |
CH02 |
Director's details changed for Gsk Consumer Healthcare Holdings No.8 Limited on 31 March 2023
|
|
|
17 May 2023 |
CH02 |
Director's details changed for Gsk Consumer Healthcare Holdings No.4 Limited on 31 March 2023
|
|
|
28 Apr 2023 |
TM01 |
Termination of appointment of David Christopher Senior as a director on 14 April 2023
|
|
|
03 Oct 2022 |
AA |
Full accounts made up to 31 December 2021
|
|
|
29 Jul 2022 |
PSC07 |
Cessation of Glaxosmithkline Consumer Healthcare Holdings (No.2) Limited as a person with significant control on 14 July 2022
|
|
|
29 Jul 2022 |
PSC02 |
Notification of Glaxosmithkline Consumer Healthcare Holdings Limited as a person with significant control on 14 July 2022
|
|
|
18 Jul 2022 |
AD01 |
Registered office address changed from 980 Great West Road Brentford TW8 9GS England to Building 5, First Floor the Heights Weybridge Surrey KT13 0NY on 18 July 2022
|
|
|
15 Jun 2022 |
CS01 |
Confirmation statement made on 15 May 2022 with updates
|
|
|
06 Apr 2022 |
TM01 |
Termination of appointment of Edinburgh Pharmaceutical Industries Limited as a director on 6 April 2022
|
|
|
06 Apr 2022 |
AP02 |
Appointment of Gsk Consumer Healthcare Holdings No.8 Limited as a director on 6 April 2022
|
|
|
06 Apr 2022 |
TM01 |
Termination of appointment of the Wellcome Foundation Limited as a director on 6 April 2022
|
|